Skip to content

Study · Randomized controlled trial · n = 82 · 2022

4 results

Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study.

Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D

Fertility and sterility13 Jun 2022Cited by 121 (Europe PMC)

PMID35710599 (opens in a new tab)DOI10.1016/j.fertnstert.2022.04.027 (opens in a new tab)PepBankPUB-35710599
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with obesity and PCOS, liraglutide 3 mg lowered body weight by 5.7% versus 1.4% with placebo at week 32.

    In plain wordsIn women with obesity and PCOS, liraglutide 3 mg lowered body weight more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change at week 32
    Study

    n = 82

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg once daily · 32 weeksAs given in this study (human).

    Measurements

    Body weight change
    −5.7%
    liraglutide 3 mg
    Body weight change
    −1.4%
    placebo

    Source sentences

    Summary
    Change in BW from baseline to week 32 was -5.7% (±0.75) with LIRA 3 mg vs. -1.4% (±1.09) with PL.
    1 context sentence
    Summary · context
    Women diagnosed with PCOS (NIH criteria) were randomly assigned to LIRA 3 mg (n = 55) or PL (n = 27) once daily for 32 weeks with lifestyle intervention.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with obesity and PCOS, liraglutide 3 mg reduced the free androgen index versus placebo, where it rose slightly.

    In plain wordsIn women with obesity and PCOS, liraglutide 3 mg lowered the free androgen index, while it rose slightly with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseFree androgen index
    Study

    n = 82

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3 mg once daily · 32 weeksAs given in this study (human).

    Source sentences

    Summary
    Free androgen index significantly reduced with LIRA 3 mg compared with the PL where the mean FAI slightly increased.
    1 context sentence
    Summary · context
    Women diagnosed with PCOS (NIH criteria) were randomly assigned to LIRA 3 mg (n = 55) or PL (n = 27) once daily for 32 weeks with lifestyle intervention.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with obesity and PCOS, more women on liraglutide 3 mg than on placebo lost at least 5% of body weight at week 32 (25 of 44 vs 5 of 23).

    In plain wordsIn women with obesity and PCOS, more women on liraglutide 3 mg than on placebo lost at least 5% of body weight.

    Peptide
    Liraglutide
    Outcome
    IncreaseWeight reduction of at least 5%
    Study

    n = 67

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg once daily · 32 weeksAs given in this study (human).

    Source sentences

    Summary
    At week 32, more participants on LIRA 3 mg than on PL achieved at least 5% weight reductions (25 of 44 vs. 5 of 23).
    1 context sentence
    Summary · context
    Women diagnosed with PCOS (NIH criteria) were randomly assigned to LIRA 3 mg (n = 55) or PL (n = 27) once daily for 32 weeks with lifestyle intervention.
  4. 04HumanRandomized controlled trialSafety outcome

    In women with obesity and PCOS, gastrointestinal events, mostly mild to moderate, occurred in 58.2% on liraglutide 3 mg versus 18.5% on placebo.

    In plain wordsIn women with obesity and PCOS, stomach and gut side effects were more common with liraglutide 3 mg than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseGastrointestinal events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    3 mg once daily · 32 weeksAs given in this study (human).

    Measurements

    Gastrointestinal events
    58.2%
    liraglutide 3 mg
    Gastrointestinal events
    18.5%
    placebo

    Source sentences

    Summary
    Gastrointestinal events, which were mostly mild to moderate, were reported in 58.2% of the LIRA 3 mg-subjects and 18.5% of PL subjects.
    1 context sentence
    Summary · context
    Women diagnosed with PCOS (NIH criteria) were randomly assigned to LIRA 3 mg (n = 55) or PL (n = 27) once daily for 32 weeks with lifestyle intervention.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03480022

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

Woman'sn = 8826 Sept 2018 to 19 May 2021

Pre Diabetes · Polycystic Ovary Syndrome · Obesity Android

Trial pageClinicalTrials.govUpdated 7 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.